NEWS
August 9, 2012
AstraZeneca buys equal say over Amylin drugs
AstraZeneca has opted to pay a further $135 million to Bristol-Myers Squibb to get an equal say in decision-making regarding drugs developed by Amylin Pharmaceuticals, the diabetes specialist...
|
|
|
|
If you already have a OnePass account, you can use it to access Business Law Currents as part of our free trial
program. If you don’t have a OnePass account, click on the link to the left to create one. You can then use this
OnePass account to access Business Law Currents as part of our free trial.
|
|